Scholars Central

Conference abstractPublished 26 Aug 2025

Conjugate based on the OmpC epitope â?? a new perspective in the prevention of shigellosis

Authors: Karina Krasna Hirszfeld

Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Shigellosis (bacterial dysentery) is an infectious disease caused by Shigella bacteria, primarily S. flexneri, leading to acute and often bloody diarrhea. It remains a significant public health issue in low- and middle-income countries, with an estimated 200,000 deaths annually, mostly among children under the age of five. Despite ongoing intensive research, no approved vaccine is currently available. Our study focuses on developing a vaccine candidate based on a unique peptide sequence derived from the outer loop of the S. flexneri 3a outer membrane protein OmpC. Due to its small size and haptenic nature, the peptide was conjugated to a larger carrier protein to enhance its immunogenicity. To enable conjugation of the peptide’s sulfhydryl group to the carrier protein, bromoacetylation was performed. This involved modifying the primary amino - groups of the carrier protein using bromoacetyl N-hydroxysuccinimide ester in a carbonate buffer, followed by coupling with the peptide.Among the carrier proteins tested, human serum albumin (HSA) allowed conjugation of 35 peptide molecules, whereas bovine serum albumin (BSA) accommodated only 3. The resulting vaccine prototype was evaluated for immunoreactivity using cord blood sera containing anti-OmpC antibodies. Immunoreactivity was assessed using dot-blot and ELISA methods using polyclonal cord blood sera as well as monoclonal antibodies specific for the RYDERY epitope. The results confirmed the high immunological reactivity of HSA–peptide conjugates. Moreover, the incorporation of the GGGGG linker increased the recognition of the peptide by antibodies.These findings suggest that a synthetic OmpC-based peptide, when properly conjugated to an immunogenic carrier, represents a promising approach for further vaccine candidate.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Clinical Trials.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical Trials
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Karina Krasna Hirszfeld”